WorldCat Identities

Lidove, Olivier

Overview
Works: 20 works in 20 publications in 2 languages and 30 library holdings
Roles: Thesis advisor, Other, Author, Publishing director
Classifications: R1, 616.3
Publication Timeline
.
Most widely held works by Olivier Lidove
Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY by Wladimir Mauhin( )

1 edition published in 2018 in English and held by 2 WorldCat member libraries worldwide

Semen and male genital tract characteristics of patients with Fabry disease: the FERTIFABRY multicentre observational study by Aline Papaxanthos-Roche( )

1 edition published in 2019 in English and held by 2 WorldCat member libraries worldwide

Of the importance of the clinical phenotypes in the interpretation of the studies dealing with Fabry disease by Wladimir Mauhin( )

1 edition published in 2019 in English and held by 2 WorldCat member libraries worldwide

Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD) by Margaret M McGovern( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

Maladie de Fabry (34 cas) : manifestations cardiaques, neurologiques, et psychiatriques by Olivier Lidove( )

1 edition published in 1998 in French and held by 2 WorldCat member libraries worldwide

Nous avons étudié 34 dossiers d'hommes atteints de maladie de Fabry. Il s'agissait de formes classiques de la maladie, ce choix se justifiant par la volonté de définir une population homogène de malades. Les atteintes cardiaques, neurologiques centrales et psychiatriques ont rarement révélé la maladie (5/34 cas). Ces complications ont par contre été retrouvées fréquemment au cours de la maladie. L'atteinte cardiaque comportait : HVG liée à une surcharge en sphingolipides (n=24), sévère et progressive avec l'âge ; HTA (n=13) ; coronaropathie (n=6) ; fibrillation auriculaire (n=3) ; troubles de conduction (n=12). La moitié des patients avaient un espace PR ≤ 0,12 seconde. Onze patients avaient au moins une valvulopathie : insuffisance mitrale (n=10, dont 4 prolapsus), rétrécissement aortique (n=4), insuffisance aortique (n=3). Trois de ces 11 patients ont développé une endocardite. Seuls 6 malades n'ont pas eu d'atteinte cardiaque au cours de leur évolution. Dix patients ont eu au total 18 accidents vasculaires cérébraux (AVC). Tous les AVC étaient ischémiques, avec un âge moyen de 35 ans lors du premier épisode. Le territoire concerné était préférentiellement vertébro-basilaire (n=10=, plus rarement carotidien interne (n=5) ou indéterminé (n=3=. Quatre de ces patients ont évolué vers une dégradation progressive des fonctions supérieures. Les autres atteintes psychiatriques concernaient 8 malades : dépression (7) avec un suicide et une défenestration, auto-mutilations (1). D'après cette série, nous avons pu estimer la médiane de survie rénale à 50 ans. Avant le stade de l'insuffisance rénale terminale, le néphrologue est souvent confronté aux AVC, tandis qu'après le début du traitement de suppléance, les complications cardiaques sont au premier plan
Co-infection VIH et Histoplasma capsulatum variant capsulatum en France métropolitaine à l'ère des multithérapies anti-rétrovirales by Vincent Peigne( Book )

1 edition published in 2010 in French and held by 2 WorldCat member libraries worldwide

Histoplasma capsulatum var. capsulatum histoplasmosis is not endemic in metropolitan France. Extra-pulmonary histoplasmosis is an AIDS-defining opportunistic infection. Few data are available about AIDS-related histoplasmosis in non-endemic areas. All (i.e. 64) AIDS-related histoplasmosis cases diagnosed in metropolitan France between 1997 and 2006 have been included in the retrospective study. Analysis of these cases indicated that histoplasmosis can occur more than 15 years after the last travel in an endemic area, that histoplasmosis is frequently (42%) the first HIV-infection manifestation and that patients with histoplasmosis are deeply immucompromised (mean CD4 count 28/µL). Muco-cutaneous lesions (45%) and hemophagocytic syndrome (14%) are suggestive of histoplasmosis. High early mortlaty rate (23%) is a plea for an ealier diagnosis. Direct examination and fungal cultures are the most useful diagnosis tools. Anti-histoplasma antibodies detection sensitvity is very low. The usefulness of galactomannan remains to be evaluated. Interestingly, immune restoration inflammatory syndrome is frequent (13%)
Clinical value of a [18F]-FDG PET-CT muscle-to-muscle SUV ratio for the diagnosis of active dermatomyositis by Nihal Martis( )

1 edition published in 2019 in English and held by 2 WorldCat member libraries worldwide

Élaboration d'un système de classification phénotypique et de sévérité des patients atteints de maladie de Fabry à partir des données de la cohorte française FFABRY by Wladimir Mauhin( )

1 edition published in 2018 in French and held by 2 WorldCat member libraries worldwide

La maladie de Fabry est une maladie lysosomale liée à l'X secondaire à un déficit en alpha-galactosidase A. La présentation classique, historique, est caractérisée par des acroparesthésies précoces, la survenue progressive d'une insuffisance rénale puis d'une cardiomyopathie, le phénotype non classique est lui limité ou largement dominé par l'atteinte cardiaque. Grâce aux données de la cohorte française FFABRY (104 patients), nous avons établi un nouveau score de sévérité simple basé sur des variables objectives et statistiquement significatives puis mis en évidence que l'absence d'acroparesthésie et/ou de cornée verticillée suffit à définir les hommes non classiques (sensibilité de 82,3%, une spécificité de 95%). Ainsi, on identifiait 29 hommes classiques, 25 hommes non classiques et 50 femmes auxquelles la classification n'est pas applicable. Le phénotype classique est associé à un déclin du débit de filtration glomérulaire plus sévère (-2,4ml contre -1,7ml/min/an ; p<0,01), la survenue plus précoce d'événements cardiaques sévères (médiane de survie 50,0 vs 60,0 ans ; p=0,012), et la survenue d'accidents vasculaires cérébraux. Plus de 40% des patients des deux sexes présentent des acouphènes et/ou une hypoacousie. Après 50 ans, les hommes classiques ont un score de sévérité totale plus élevé (médianes 16,3 vs 10,0 ; p=0,009). Finalement, l'absence de cornée verticillée et d'acroparesthésie permet l'identification des patients non-classiques qui représentent aujourd'hui près de la moitié des patients, avec un pronostic moins sévère. Cette classification phénotypique associée au score de sévérité est nécessaire à l'évaluation objective des traitements actuels et à venir
RECHUTES DES VASCULARITES ASSOCIEES AUX ANCA EN HEMODIALYSE (DES MEDECINE INTERNE) by JEAN-EMMANUEL KAHN( Book )

1 edition published in 2000 in French and held by 2 WorldCat member libraries worldwide

Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1 by Jérôme Stirnemann( )

1 edition published in 2015 in English and held by 2 WorldCat member libraries worldwide

Treatment needs and expectations for Fabry disease in France: development of a new Patient Needs Questionnaire by Esther Noël( )

1 edition published in 2019 in English and held by 2 WorldCat member libraries worldwide

Dissection spontanée de l'artère rénale : à propos de cinq observations by Serge Milosavljevic( )

1 edition published in 1999 in French and held by 2 WorldCat member libraries worldwide

Nous rapportons cinq observations de dissections isolées spontanées de l'artère rénale diagnostiquées dans le service de néphrologie de l'hôpital Necker. - La dissection isolée, spontanée de l'artère rénale reste une affection peu fréquente mais probablement sous-estimée car un tiers des cas de la littérature est diagnostiqué lors d'autopsies. - Cette pathologie prédomine de façon encore inexpliquée chez l'homme jeune. - Le tableau clinique est peu spécifique et reste dominé par une hypertension artérielle associée à un syndrome douloureux à type de "colique néphrétique". - L'artériographie est l'examen clé du diagnostic. - Le traitement médical représente une alternative au traitement chirurgical, car avec l'obtention de chiffres tensionnels parfaits, l'évolution est favorable en terme de fonction rénale
Determinants of Hydroxychloroquine Blood Concentration Variations in Systemic Lupus Erythematosus( )

1 edition published in 2015 in English and held by 1 WorldCat member library worldwide

Abstract Objective Blood concentrations of hydroxychloroquine (HCQ) vary widely among patients with systemic lupus erythematosus (SLE). A pharmacokinetic/pharmacodynamic relationship has been found in different situations, and a very low blood concentration of HCQ is a simple marker of nonadherence to treatment. Therefore, interest in blood HCQ concentration measurement has increased, but little is known about factors that influence blood HCQ concentration variability. This study was undertaken to analyze determinants of blood HCQ concentrations. Methods We conducted a retrospective analysis of patient data, including data from the Plaquenil Lupus Systemic (PLUS) study, to determine the association of epidemiologic, clinical, and biologic factors with blood HCQ concentrations. Data for nonadherent patients (blood HCQ concentration <200 ng/ml) were excluded. Results To examine homogeneous pharmacologic data, we restricted the analyses of the PLUS data to the 509 SLE patients receiving 400 mg/day. We found no association of ethnicity or smoking with blood HCQ concentrations and no pharmacokinetic drug-drug interaction with antacids or with inhibitors or inducers of cytochrome P450 enzymes. On multivariate analysis, high body mass index (P = 0.008), no treatment with corticosteroids (P = 0.04), increased time between the last tablet intake and measurement of blood HCQ concentrations (P = 0.017), low platelet count (P <0.001), low neutrophil count (P <0.001), and high estimated creatinine clearance (P <0.001) were associated with low blood HCQ concentrations. In 22 SLE patients with chronic renal insufficiency (median serum creatinine clearance 52 ml/minute [range 23-58 ml/minute]) who received 400 mg/day HCQ, the median blood HCQ concentration was significantly higher than that in the 509 patients from the PLUS study (1, 338 ng/ml [range 504-2, 229 ng/ml] versus 917 ng/ml [range 208-3316 ng/ml]) (P <0.001). Conclusion We provide a comprehensive analysis of determinants of blood HCQ concentrations. Because this measurement is increasingly being used, these data might be useful for clinicians
Treatment of Systemic Necrotizing Vasculitides in Patients Aged Sixty-Five Years or Older: Results of a Multicenter, Open-Label, Randomized Controlled Trial of Corticosteroid and Cyclophosphamide-Based Induction Therapy1( )

1 edition published in 2015 in English and held by 1 WorldCat member library worldwide

Abstract : Objective: To investigate a new therapeutic strategy, with rapid corticosteroid dose tapering and limited cyclophosphamide (CYC) exposure, for older patients with systemic necrotizing vasculitides (SNVs; polyarteritis nodosa [PAN], granulomatosis with polyangiitis [Wegnener's] [GPA], microscopic polyangiitis [MPA], or eosinophilic GPA [Churg-Strauss] [EGPA]). Methods: A multicenter, open-label, randomized controlled trial comprising patients e"5 years old and newly diagnosed as having SNV was conducted. The experimental treatment consisted of corticosteroids for <" months and a maximum of six 500-mg fixed-dose intravenous (IV) CYC pulses, every 2-3 weeks, then maintenance azathioprine or methotrexate. The control treatment included <"6 months of corticosteroids for all patients, combined with 500 mg/m 2 IV CYC pulses, every 2-3 weeks until remission, then maintenance for all patients with GPA or MPA and for those with EGPA or PAN with a Five-Factors Score (FFS) of e". Randomization used a 1:1 ratio computer-generated list and was performed centrally with sealed opaque envelopes. The primary outcome measure was e" serious adverse event (SAE) occurring within 3 years of followup. Secondary outcome measures included remission and relapse rates. Results: Among the 108 patients randomized, 4 were excluded (early consent withdrawal or protocol violation). Mean ± SD age at diagnosis was 75.2 ± 6.3 years. Analysis at 3 years included 53 patients (21 GPA, 21 MPA, 8 EGPA, and 3 PAN) in the experimental arm and 51 patients (15 GPA, 23 MPA, 6 EGPA, and 7 PAN) in the conventional arm. In total, 32 (60%) versus 40 (78%) had e" SAE (P = 0.04), most frequently infections; 6 (11%) versus 7 (14%) failed to achieve remission (P = 0.71); 9 (17%) versus 12 (24%) died (P = 0.41); and 20 (44%) of 45 versus 12 (29%) of 41 survivors in remission experienced a relapse (P = 0.15). Conclusion: For older SNV patients, an induction regimen limiting corticosteroid exposure and with fixed low-dose IV CYC pulses reduces SAEs in comparison to conventional therapy, and does not affect the remission rate. Three-year relapse rates remain high for both arms
Maladie de Fabry atlas iconographique( Book )

in French and held by 1 WorldCat member library worldwide

Prevalence of Raynaud Phenomenon and Nailfold Capillaroscopic Abnormalities in Fabry Disease( )

1 edition published in 2015 in English and held by 1 WorldCat member library worldwide

Abstract Abstract Fabry disease (FD) is a lysosomal disorder leading to progressive systemic involvement, including microvascular damage that leads to neurological and cardiovascular disorders. We hypothesize that the latter could be documented at an early stage by performing a microcirculation study with nailfold capillaroscopy and evaluation of Raynaud phenomenon. The objective was to measure the prevalence of Raynaud phenomenon and nailfold capillaroscopic abnormalities in FD. This cross-sectional study included a standardized questionnaire and a nailfold capillaroscopy that assessed previously reported patterns in FD (dystrophic and giant capillaries, avascular fields, irregular architecture, dilatation and density of capillaries, hemorrhage), and was conducted on 32 Fabry patients and 39 controls. Capillaroscopic photographs were reviewed by 2 independent blinded investigators. Twelve Fabry patients (38%) suffered from Raynaud phenomenon, 5 were males (ie, 50% of male Fabry patients), compared with 2 controls (13%) (P <0.001), of whom none were males (P <0.001). Raynaud phenomenon was concomitant or before the occurrence of pain in the extremities in 42% of Fabry patients. More ramified capillaries were significantly observed in Fabry patients (12/32, 38%) than in controls (5/39, 13%, P = 0.016). Secondary Raynaud phenomenon should lead to screening for FD, especially in men. By extension, in high-risk populations for FD, the presence of Raynaud phenomenon and ramified capillaries should be assessed
Cardiac device implantation in Fabry disease( )

1 edition published in 2016 in English and held by 1 WorldCat member library worldwide

Abstract : Abstract: The incidence and predictive factors of arrhythmias and/or conduction abnormalities (ACAs) requiring cardiac device (CD) implantation are poorly characterized in Fabry disease (FD). The aim of our retrospective study was to determine the prevalence, incidence, and factors associated with ACA requiring CD implantation in a monocentric cohort of patients with confirmed FD who were followed up in a department of internal medicine and reference center for FD. Forty-nine patients (20M, 29F) were included. Nine patients (4M, 5F; 18%) had at least one episode of ACA leading to device therapy. Six patients (4M/2F) required a pacemaker (PM) for sinus node dysfunction (n = 4) or atrioventricular disease (n = 2). One female patient required an internal cardioverter-defibrillator (ICD) to prevent sudden cardiac death because of nonsustained ventricular tachycardia (nSVT). One female patient required PM-ICD for sinus node dysfunction and nSVT. One patient underwent CD implantation before the diagnosis of FD. The annual rate of CD implantation was estimated at 1.90 per 100 person years. On univariate analysis at the end of the follow-up period, the factors associated with ACAs requiring CD implantation were as follows: delayed diagnosis of FD, delayed initiation of enzyme replacement therapy, age at the last follow-up visit, and severe multiorgan phenotype (hypertrophic cardiomyopathy, chronic kidney disease, and/or sensorineural hearing loss). On multivariate analysis, age at diagnosis of FD and age at the last follow-up visit were independently associated with an increased risk of ACAs requiring CD (P <0.05). Considering the high frequency of ACAs requiring CD implantation and the risk of sudden death in patients with FD, regular monitoring is mandatory, especially in patients with a late diagnosis of FD and/or with a severe phenotype. Regular Holter ECGs, therapeutic education of patients, and deliverance of an emergency card including a phenotype summary are crucial in the care of FD patients. Available guidelines for device therapy and the efficacy of enzyme replacement therapy for arrhythmias or conduction abnormalities are discussed
Myélopathies et maladies systémiques : à propos de deux observations et revue de la littérature by Caroline Guyot( Book )

1 edition published in 2005 in French and held by 1 WorldCat member library worldwide

La maladie de Fabry en pratique : la reconnaître, la diagnostiquer, l'annoncer, la traiter( Book )

in French and held by 0 WorldCat member libraries worldwide

La maladie de Fabry en pratique : sémiologie actualisée, diagnostic codifié, conseil génétique simplifié, traitement en pratique( Book )

1 edition published in 2006 in French and held by 0 WorldCat member libraries worldwide

 
moreShow More Titles
fewerShow Fewer Titles
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.95 (from 0.88 for Cardiac de ... to 1.00 for Dissection ...)

Languages
English (11)

French (9)